Phantom Neuro receives approval for CYBORG first-in-human BCI study in Australia — peripheral nerve approach
Summary
Australian BCI company Phantom Neuro announced approval of its first-in-human clinical study, CYBORG, for the Phantom X system in Australia in April 2026. The Phantom X uses a peripheral nerve interface approach rather than cortical implants, targeting motor restoration in amputees and spinal cord injury patients. Australia's TGA regulatory pathway and NHMRC research infrastructure have made it an increasingly attractive first-in-human jurisdiction for BCI companies.
Why it matters
Australia approving a peripheral nerve BCI first-in-human study adds a fourth national regulatory jurisdiction — alongside the US (FDA), UK (MHRA), and China (NMPA) — actively enabling novel BCI human studies. Australia's faster IRB processes and experienced neurosurgical centers make it an increasingly strategic first-in-human location for companies that then leverage Australian data in FDA submissions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial